Zobrazeno 1 - 10
of 473
pro vyhledávání: '"Raymond L, Benza"'
Publikováno v:
European Respiratory Review, Vol 33, Iss 171 (2024)
The nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) pathway plays a key role in the pathogenesis of pulmonary hypertension (PH). Targeted treatments include phosphodiesterase type 5 inhibitors (PDE5i) and s
Externí odkaz:
https://doaj.org/article/fcc206931a994f66a90b04a503a8a748
Autor:
Raymond L. Benza, Philip B. Adamson, Deepak L. Bhatt, Fredrik Frick, Gunnar Olsson, Niklas Bergh, Björn Dahlöf
Publikováno v:
Pulmonary Circulation, Vol 14, Iss 1, Pp n/a-n/a (2024)
Abstract Although rare, pulmonary arterial hypertension (PAH) is associated with substantial morbidity and a median survival of approximately 7 years, even with treatment. Current medical therapies have a primarily vasodilatory effect and do not modi
Externí odkaz:
https://doaj.org/article/ba9468a5ec3649d2ad1715aea913abbe
Autor:
Kellie Morland, Christian Gerges, Jean Elwing, Scott H. Visovatti, Jason Weatherald, Kari R. Gillmeyer, Sandeep Sahay, Stephen C. Mathai, Athénaïs Boucly, Paul G. Williams, Sivadasanpillai Harikrishnan, Evan P. Minty, Lukas Hobohm, Arun Jose, Roberto Badagliacca, Edmund M. T. Lau, Zhi‐Cheng Jing, Rebecca R. Vanderpool, Charles Fauvel, Jose Leonidas Alves Jr., Geoff Strange, Tomas Pulido, Junyan Qian, Mengtao Li, Valentina Mercurio, Jason G. E. Zelt, Victor M. Moles, Meghan M. Cirulis, Sylvia M. Nikkho, Raymond L. Benza, C. Gregory Elliott
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 4, Pp n/a-n/a (2023)
Abstract This manuscript on real‐world evidence (RWE) in pulmonary hypertension (PH) incorporates the broad experience of members of the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative Real‐World Evidence Working Gr
Externí odkaz:
https://doaj.org/article/cbfc593f3e3c499eb6df1025f764229f
Autor:
Raymond L. Benza, Veronica Franco, Mandar A. Aras, Leslie Spikes, Daniel Grinnan, Carol Satler
Publikováno v:
Respiratory Research, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Pulmonary arterial hypertension (PAH) is a progressive disease characterized by high mean pulmonary arterial pressure (≥ 20 mmHg) and remodeling of the vascular arteries. Approved therapies improve symptoms and delay clinical wo
Externí odkaz:
https://doaj.org/article/623fdde4cf1a415a91822455e8e53d4f
Autor:
Robert P. Frantz, Raymond L. Benza, Richard N. Channick, Kelly Chin, Luke S. Howard, Vallerie V. McLaughlin, Olivier Sitbon, Roham T. Zamanian, Anna R. Hemnes, Matt Cravets, Jean‐Marie Bruey, Robert Roscigno, David Mottola, Erin Elman, Lawrence S. Zisman, Hossein‐Ardeschir Ghofrani
Publikováno v:
Pulmonary Circulation, Vol 11, Iss 4, Pp 1-7 (2021)
Aberrant kinase signaling that involves platelet‐derived growth factor receptor (PDGFR) α/β, colony stimulating factor 1 receptor (CSF1R), and stem cell factor receptor (c‐KIT) pathways may be responsible for vascular remodeling in pulmonary ar
Externí odkaz:
https://doaj.org/article/e7c6ee3ea34a41f89721a2c6c04b54de
Autor:
Raymond L. Benza, David Langleben, Anna R. Hemnes, Anton Vonk Noordegraaf, Stephan Rosenkranz, Thenappan Thenappan, Paul M. Hassoun, Ioana R. Preston, Stefano Ghio, Roberto Badagliacca, Carmine D. Vizza, Irene M. Lang, Christian Meier, Ekkehard Grünig
Publikováno v:
European Respiratory Review, Vol 31, Iss 166 (2022)
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are conseq
Externí odkaz:
https://doaj.org/article/60fdf4e6cc5e4748952b0605408e7323
Autor:
Nicholas S. Hill, Jeremy P. Feldman, Sandeep Sahay, Raymond L. Benza, Ioana R. Preston, David Badesch, Robert P. Frantz, Savan Patel, Ashley Galloway, Todd M. Bull, the INSPIRE study investigators
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 3, Pp n/a-n/a (2022)
Abstract The INSPIRE trial was a Phase 3, open‐label, multicenter trial (LTI‐301) that enrolled patients with pulmonary arterial hypertension (PAH) ≥ 18 years of age who transitioned to Yutrepia from nebulized treprostinil (Transition) or added
Externí odkaz:
https://doaj.org/article/d3d486acf448475aa616783826502355
Autor:
William H. Marshall V, Stephen Gee, Woobeen Lim, Lauren T. Lastinger, Michael Cackovic, Raymond L. Benza, Curt J. Daniels, Elisa A. Bradley, Saurabh Rajpal
Publikováno v:
International Journal of Cardiology Congenital Heart Disease, Vol 8, Iss , Pp 100354- (2022)
Background: Pulmonary hypertension (PH) due to left heart disease (World Health Organization (WHO) Group 2 PH) is the largest PH subgroup, however most reports of PH in pregnancy focus on patients with pulmonary arterial hypertension (WHO Group 1 PH)
Externí odkaz:
https://doaj.org/article/e9a6bf28ea444cafbf38b30179428b43
Autor:
Samuel B. Brusca, Jason M. Elinoff, Yvette Zou, Moon Kyoo Jang, Hyesik Kong, Cumhur Y. Demirkale, Junfeng Sun, Fayaz Seifuddin, Mehdi Pirooznia, Hannah A. Valantine, Carl Tanba, Abhishek Chaturvedi, Grace M. Graninger, Bonnie Harper, Li-Yuan Chen, Justine Cole, Manreet Kanwar, Raymond L. Benza, Ioana R. Preston, Sean Agbor-Enoh, Michael A. Solomon
Publikováno v:
Circulation. 146(14)
Background: Cell-free DNA (cfDNA) is a noninvasive marker of cellular injury. Its significance in pulmonary arterial hypertension (PAH) is unknown. Methods: Plasma cfDNA was measured in 2 PAH cohorts (A, n=48; B, n=161) and controls (n=48). Data were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bddf055d914a456677cd9a6775538e7
https://pubmed.ncbi.nlm.nih.gov/36004627
https://pubmed.ncbi.nlm.nih.gov/36004627
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
The combination of bosentan and sildenafil is commonly used to treat patients with pulmonary arterial hypertension (PAH); however, there is evidence of a significant drug interaction between these two medications. We sought to evaluate the safety and
Externí odkaz:
https://doaj.org/article/0cab27788e5047cc8fe8b7a450e5f4d8